宁泌泰-特拉唑嗪与普适泰治疗慢性非细菌性前列腺炎

目的: 评价宁泌泰联合特拉唑嗪与普适泰治疗慢性非细菌性前列腺炎(CNP)的临床疗效。方法: 按照美国国立卫生研究所(NIH)分类标准,筛选出118例CNP患者,分为宁泌泰-特拉唑嗪组60例和普适泰组58例,分别口服药物8周,观察治疗前后临床症状改善状况,每位患者行前列腺炎症状程度评分(CPSI),并对两种药物治疗效果进行评价。结果: 治疗8周后,两组临床症状改善明显,表现在NIH-CPSI评分、排尿症状评分和疼痛不适评分均明显降低(P<0.01)。两组疗效差异无显著性(P>0.05)。两组治疗后排尿症状评分和疼痛不适评分差异均有显著性(P<0.01)。结论: 宁泌泰联合特拉唑嗪与普适泰治疗慢性非细菌性前列腺炎疗效肯定;宁泌泰联合特拉唑嗪治疗以排尿症状为主的慢性非细菌性前列腺炎疗效好,普适泰治疗以前列腺痛为主的症状疗效好。

Evaluation of ningmitai-terazosin and prostat for treatment of chronic nonbacterial prostatitis

Objective: To evaluate and compare the efficacy of ningmitai-terazosin and prostat in treatment of chronic nonbacterial prostatitis(CNP).Methods: Based on National Institutes of Health(NIH) classification,118 cases of CNP were randomly divided into ningmitai-terazosin group(60 cases) and prostat group(58 cases).The drugs were administered for 8 weeks and the clinical symptoms before and after treatment were surveyed.The chronic prostatitis symptom index(CPSI) of each patient was evaluated.Results: After 8 weeks' treatment,the symptoms of the two groups improved significantly(P<0.01).The difference in CNP was not significant between the two groups(P>0.05).Compared with pretreatment,the difference in the reduction of micturition scores and ache scores was significant between the two groups(P<0.01).Conclusions: Both ningmitai-terazosin and prostat have a positive effect on CNP.Ningmitai-terazosin is more effective in relieving the stimulus of urethra,while prostat can rapidly relieve the pelvic pain.